Back

A multidimensional atlas of human glioblastoma organoids reveals highly coordinated molecular networks and effective drugs

Wang, C.; Sun, M.; Shao, C.; Schlicker, L.; Zhuo, Y.; Harim, Y.; Peng, T.; Tian, W.; stoeffler, N.; Schneider, M.; Helm, D.; Mallm, J.-P.; Wu, Y.; Schulze, A.; LIU, H.-K.

2023-01-24 cancer biology
10.1101/2023.01.24.525374 bioRxiv
Show abstract

Recent advances in the genomics of glioblastoma (GBM) led to the introduction of molecular neuropathology but failed to translate into treatment improvement. This is largely attributed to the genetic and phenotypic heterogeneity of GBM, which are considered the major obstacle to GBM therapy. Here, we use advanced human GBM organoid (LEGO: Laboratory Engineered Glioblastoma Organoid) and provide an unprecedented comprehensive characterization of LEGO models using single-cell transcriptome, DNA methylome, metabolome, lipidome, proteome, and phospho-proteome analysis. We discovered that genetic heterogeneity dictates functional heterogeneity across molecular layers and demonstrates that NF1 mutation drives mesenchymal signature. Most importantly, we found that glycerol lipid reprogramming is a hallmark of GBM, and several targets and drugs were discovered along this line. We also provide a genotype-based drug reference map using LEGO-based drug screen. This study provides novel human GBM models and a research path toward effective GBM therapy.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.